Use of the new oxygen-depolarized cathode technology reduces power consumption and CO 2 emissions. In June Bayer receives the 2008 Environmental Award in the category “Environmentally Friendly Technologies” by the Federation of German Industries (BDI). The program’s goals include a further reduction in CO 2 emissions from Bayer’s production facilities. November sees the launch of the integrated, Group-wide Bayer Climate Program. 180 young people from 85 countries debate global environmental issues.Ĭentennial celebration: in September, the 100th season of the Bayer Cultural Affairs Department gets under way. In August, Bayer hosts the TUNZA International Youth Conference of the United Nations Environment Programme (UNEP) in Leverkusen, the first time this youth environmental summit has been held in central Europe. In March it is announced that the BayArena stadium, home of German Bundesliga soccer team Bayer 04 Leverkusen, is to be modernized and enlarged to accommodate a crowd of over 30,000. In January, Bayer sells the Diagnostics Division of Bayer HealthCare to Siemens AG, Munich, for €4.2 billion. Bayer Schering Pharma AG, headquartered in Berlin, now operates together with Bayer’s existing Pharmaceuticals business as a division of the Bayer HealthCare subgroup. In January, an Extraordinary Stockholders’ Meeting of Bayer Schering Pharma AG resolves to effect a “squeeze-out” of the remaining minority stockholders. In December, Schering AG is officially renamed Bayer Schering Pharma AG. In July, Bayer gains control of 92.4 percent of the approximately 191 million outstanding Schering shares. In March, Bayer announces a public takeover offer for Schering AG, Berlin, Germany. Food and Drug Administration approves sorafenib (tradename: Nexavar™), an active ingredient jointly developed by Bayer HealthCare and Onyx Pharmaceuticals Inc., for the treatment of advanced renal cell carcinoma. This company continues Bayer’s chemicals business and parts of its polymers business. Lanxess AG is spun off from the Bayer Group on January 28. In January, Bayer completes the acquisition of the Roche consumer health business, advancing to become one of the world’s top three suppliers of nonprescription medicines. In June, Bayer becomes the first private-sector partner to the United Nations Environment Programme (UNEP) in the area of youth and environment.
In January the Group’s world-famous trademark, the Bayer Cross, celebrates its centennial. The subgroup Bayer MaterialScience AG and the service companies Bayer Business Services GmbH and Bayer Industry Services GmbH & Co. In October, the subgroups Bayer Chemicals AG and Bayer HealthCare AG and the service company Bayer Technology Services GmbH gain legal independence as part of the reorganization of the Bayer Group. On December 6, the company‘s management announces plans to establish independent operating subsidiaries under the umbrella of a management holding company.īayer CropScience AG is launched in October as the first legally independent Bayer subgroup. Bayer Pharma Schering currently employs around 40,000 people worldwide.Bayer acquires Aventis CropScience for €7.25 billion, making it a world leader in crop protection. The company stated that there will be no direct dismissals until mid 2008 in Berlin.
Another 250 employees will be offered different positions in the Bayer group. Regarding the 950 jobs to be lost in Berlin, 350 employees have already accepted individual solutions, such as retirement schemes or cancellation agreements including compensation payments. There is no information available on the remaining 550 job cuts in Germany. In Germany 950 jobs will be lost at the company's headquarter in Berlin, where the company currently employs 6,000 people. All in all, 20 research projects will be terminated. According to a June 2007 press release, the research and development divisions will be strongly affected by the job cuts. As a result of this, 6,100 jobs will be cut worldwide: 3,150 in Europe, 1,000 in the USA, 750 in Asia-Pacific region and Japan and 1,200 in Latin America and Canada. The company stated in a press release that starting from 2009, it will seek to save 700 million Euro per year (800 million Euro according to a June 2007 press release) following synergies from the merger. On 1 March 2007, Bayer Schering announced details of its restructuring scheme following the merger. In June 2006 the Schering AG and the pharmaceutical division of Bayer's subsidiary Bayer HealthCare were merged into Bayer Schering Pharma AG, a manufacturer of pharmaceutical products.
0 kommentar(er)
